---
title: "Eli Lilly's lepodisiran small interfering RNA therapy Phase 2 clinical results are positive for treating hereditary heart disease"
description: "Eli Lilly announced on March 30, 2025, that lepodisiran achieved positive results in the Phase 2 ALPACA clinical study. The therapy significantly reduced levels of the hereditary cardiovascular risk f"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/234229321.md"
published_at: "2025-04-02T13:09:08.000Z"
---

# Eli Lilly's lepodisiran small interfering RNA therapy Phase 2 clinical results are positive for treating hereditary heart disease

> Eli Lilly announced on March 30, 2025, that lepodisiran achieved positive results in the Phase 2 ALPACA clinical study. The therapy significantly reduced levels of the hereditary cardiovascular risk factor Lp(a), with a maximum reduction of 93.9%. The study showed that after receiving different doses of lepodisiran, patients' Lp(a) levels continued to decrease over nearly 18 months, with some patients experiencing effects lasting up to 1.5 years

According to Zhitong Finance APP, on March 30, 2025, **Eli Lilly (LLY.US) announced positive results for lepodisiran in Phase 2 clinical trials.** **Lepodisiran is an investigational small interfering RNA (siRNA) therapy designed to reduce the production of lipoprotein(a) \[Lp(a)\]. Lp(a) is a risk factor for hereditary heart disease.** In the Phase 2 ALPACA study, lepodisiran reduced Lp(a) levels by an average of 93.9% during the period from day 60 to day 180 after treatment at the highest tested dose (400mg), achieving the primary endpoint of the study. Participants receiving lepodisiran at doses of 16mg and 96mg had Lp(a) levels reduced by 40.8% and 75.2%, respectively, during the same time period.

Lepodisiran also achieved several secondary endpoints. In the nearly 18-month study, all assessment time points showed a reduction in Lp(a) levels after a single or double administration of lepodisiran at three tested doses (16mg, 96mg, or 400mg). The study was designed to administer lepodisiran (16mg, 96mg, or 400mg) once at baseline and again at day 180, with an additional group receiving lepodisiran 400mg at baseline and a placebo at day 180. The effects of additional doses of lepodisiran have yet to be determined

### Related Stocks

- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eli Lilly just delivered fantastic news to investors | Eli Lilly shares have climbed in the double digits this year. | [Link](https://longbridge.com/en/news/269703566.md) |
| Watts Gwilliam & Co. LLC Reduces Position in Eli Lilly and Company $LLY | Watts Gwilliam & Co. LLC reduced its holdings in Eli Lilly and Company by 70.8% in Q2, now owning 1,083 shares worth $82 | [Link](https://longbridge.com/en/news/269876200.md) |
| ConocoPhillips considers selling Permian assets worth $2 billion, Bloomberg News reports | Feb 20 (Reuters) - ConocoPhillipsis exploring a sale of some of its Permian Basin assets as part of a broader streamlini | [Link](https://longbridge.com/en/news/276478732.md) |
| IronBridge Private Wealth LLC Has $905,000 Holdings in Apple Inc. $AAPL | IronBridge Private Wealth LLC reduced its stake in Apple Inc. (NASDAQ:AAPL) by 77.3% in Q3, holding 3,555 shares valued  | [Link](https://longbridge.com/en/news/276436345.md) |
| Financial Advocates Investment Management Lowers Stock Position in Meta Platforms, Inc. $META | Financial Advocates Investment Management reduced its stake in Meta Platforms, Inc. by 66.7% in Q3, now holding 2,343 sh | [Link](https://longbridge.com/en/news/276432394.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
